368 filings
Page 5 of 19
EFFECT
hau1cju4ub zo13
4 May 23
Notice of effectiveness
12:15am
CORRESP
rma dzgf3q
1 May 23
Correspondence with SEC
12:00am
DEFA14A
3xf9291i t0mgqv5sn
28 Apr 23
Additional proxy soliciting materials
4:15pm
8-K
6pa2f qt1p73w
17 Apr 23
Avenue Therapeutics Announces Regulatory Update Based on Type C Meeting with FDA and Next Steps in the Development of IV Tramadol
4:06pm
UPLOAD
y4t2 8htg8
17 Apr 23
Letter from SEC
12:00am
4
tiqnt6hfv pfcw3e8o
4 Apr 23
Change in insider ownership
4:08pm
8-K
gatlyki 89r
30 Mar 23
Avenue Therapeutics Reports Full Year 2022 Financial Results and Recent Corporate Highlights
4:07pm
8-K
3znobxa
8 Mar 23
Avenue Therapeutics Provides Regulatory Update on IV Tramadol and Other Corporate Updates
4:10pm
8-K
bzfa6s8
2 Mar 23
Entry into a Material Definitive Agreement
8:05am
SC 13G/A
vkqbnjtcc mtb5ra3dk
14 Feb 23
AVENUE THERAPEUTICS / CVI Investments ownership change
11:22am
D
z5lkikkzneq29qcc
14 Feb 23
$242.54 k in options, sold $242.54 k, 1 investor
9:15am
S-8
gsr5bzini v1hxsch6k
10 Feb 23
Registration of securities for employees
4:06pm
8-K
vdj0 a5ad8df916
10 Feb 23
Amendments to Articles of Incorporation or Bylaws
4:05pm
8-K
m82oj
3 Feb 23
Departure of Directors or Certain Officers
4:05pm
8-K
rnf7ljp zu
1 Feb 23
Avenue Therapeutics Announces $3.25 Million Registered Direct and Private Placement Priced at the Market Under Nasdaq Rules
8:15am
424B5
tzbdi
31 Jan 23
Prospectus supplement for primary offering
12:05pm
8-K
tifeh993h885xfl6tpo
25 Jan 23
Changes in Registrant's Certifying Accountant
4:10pm